New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C

Theresa Boyle, MD, PhD, discusses the role of concurrent molecular testing in lung cancer.

John Longshore, PhD, FACMG, discusses key molecular markers in metastatic lung cancer.

Alexander Spira, MD, PhD, FACP, discusses the role of broad molecular testing in lung cancer.

Benjamin P. Levy, MD, discusses the importance of testing for KRAS mutations in lung cancer.

Nasser H. Hanna, MD, discusses his approach to biomarker testing in lung cancer.

John Longshore, PhD, FACMG, discusses selecting between comprehensive vs single-gene molecular testing in lung cancer.

Theresa Boyle, MD, PhD, discusses the current approach to biomarker testing in lung cancer.

On February 3, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of lung cancer to participate in a virtual workshop to discuss the emerging treatment landscape of targeted therapies in NSCLC. This article summarizes key data about KRAS G12C as a therapeutic target as well as insights from stakeholder discussions regarding this topic.